Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TB/FLU-04L Tuberculosis Vaccine
NCT02501421Phase 1Completed
- Sponsor
- Research Institute for Biological Safety Problems
- Start
- Oct 2013
- Primary completion
- Apr 2014
- Modality
- Viral Vector Vaccines
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing TB/FLU-04L with Placebo (2 arms). Primary endpoints: Immediate reactions at 2 hours, Solicited local and systemic reactions at 7 days and 2 more. Started Oct 2013; status: completed.
02
Drugs
TB/FLU-04L
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02501421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501421.